CMPX, NCM

Compass Therapeutics, Inc. (CMPX)

Price (as of October 30)

3.18USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

CGEM

Cullinan Oncology, Inc.

-0.17

ACLX

Arcellx, Inc.

-0.17

BLPH

Bellerophon Therapeutics, Inc.

-0.13

CDAK

Codiak BioSciences, Inc.

-0.1

BTX

Eterna Therapeutics Inc.

-0.1

ANTX

AN2 Therapeutics, Inc.

-0.1

BWV

Blue Water Vaccines, Inc.

-0.09

BOLT

Bolt Biotherapeutics, Inc.

-0.09

CELZ

Creative Medical Technology Holdings, Inc.

-0.09

BLCM

Bellicum Pharmaceuticals, Inc.

-0.09

Show more

Highest within Industry

Symbol Correlation

ADVM

Adverum Biotechnologies, Inc.

0.26

CCXI

ChemoCentryx, Inc.

0.17

AKTX

Akari Therapeutics, Plc

0.12

AURA

Aura Biosciences, Inc.

0.11

BMEA

Biomea Fusion, Inc.

0.11

AKUS

Akouos, Inc.

0.11

ARMP

Armata Pharmaceuticals, Inc.

0.1

ADGI

Adagio Therapeutics, Inc.

0.1

ADMA

ADMA Biologics, Inc.

0.1

ATNF

180 Life Sciences Corp.

0.1

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company’s product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.